Jasper Therapeutics (JSPR)
(Delayed Data from NSDQ)
$21.60 USD
+1.68 (8.43%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $21.62 +0.02 (0.09%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JSPR 21.60 +1.68(8.43%)
Will JSPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JSPR
Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
JSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going
Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength
Other News for JSPR
Briquilimab’s Market Edge and Untapped Value: A Buy Rating for Jasper Therapeutics
Jasper Therapeutics initiated with bullish view at Stifel, here's why
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Jasper Therapeutics Board Changes and New Director’s Arrival
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors